Vaccines are safe, highly effective, and they work by training your immune system to respond to disease. This post breaks down why measles cases dropped dramatically after vaccination and why hepatitis B prevention matters—especially for kids—so you can make informed choices.
EVUSHELD: Protection for the Immunocompromised
EVUSHELD (tixagevimab & cilgavimab) is designed to offer protection from COVID-19 infections in patients who cannot mount an adequate immune response from COVID-19 vaccination (or for patients who cannot receive the vaccine for medical reasons).
EVUSHELD is specifically designed for patients that are immunocompromised. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)
Want an EVUSHELD injection? Fill out the form below:
0 New comments